Literature DB >> 29362905

Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery.

Shahab Ahmed1, Cathy Eng2.   

Abstract

Rectal cancer has been successfully managed in the last couple of decades. In the USA, as the initial approach, neoadjuvant concurrent chemoradiation has been associated not only with decrease in tumor size and recurrence but also with higher resection rate with minimal side effects. Data support that addition of chemotherapy to radiotherapy is superior to radiotherapy alone in the neoadjuvant setting. Recent debates have addressed the question of administration of adjuvant chemotherapy following surgery. In this article, we discuss the role of chemotherapy in both the neoadjuvant and the adjuvant settings for locally advanced rectal cancer.

Entities:  

Keywords:  Adjuvant therapy; Colorectal cancer; Locally advanced rectal cancer; Neoadjuvant chemoradiation; Rectal cancer

Mesh:

Year:  2018        PMID: 29362905     DOI: 10.1007/s11912-018-0652-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  17 in total

1.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

2.  Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer.

Authors:  J V Schou; F O Larsen; L Rasch; D Linnemann; J Langhoff; E Høgdall; D L Nielsen; K Vistisen; A Fromm; B V Jensen
Journal:  Ann Oncol       Date:  2012-04-02       Impact factor: 32.976

3.  No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT).

Authors:  Aldo Sainato; Valentina Cernusco Luna Nunzia; Vincenzo Valentini; Antonino De Paoli; Enrici Riccardo Maurizi; Marco Lupattelli; Cynthia Aristei; Cristiana Vidali; Monica Conti; Alessandra Galardi; Pietro Ponticelli; Maria Luisa Friso; Tiziana Iannone; Falchetto Mattia Osti; Bruno Manfredi; Marianna Coppola; Cinzia Orlandini; Luca Cionini
Journal:  Radiother Oncol       Date:  2014-11-14       Impact factor: 6.280

4.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

5.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

6.  Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†.

Authors:  C Fernandez-Martos; X Garcia-Albeniz; C Pericay; J Maurel; J Aparicio; C Montagut; M J Safont; A Salud; R Vera; B Massuti; P Escudero; V Alonso; C Bosch; M Martin; B D Minsky
Journal:  Ann Oncol       Date:  2015-05-08       Impact factor: 32.976

7.  Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.

Authors:  A J Breugom; W van Gijn; E W Muller; Å Berglund; C B M van den Broek; T Fokstuen; H Gelderblom; E Kapiteijn; J W H Leer; C A M Marijnen; H Martijn; E Meershoek-Klein Kranenbarg; I D Nagtegaal; L Påhlman; C J A Punt; H Putter; A G H Roodvoets; H J T Rutten; W H Steup; B Glimelius; C J H van de Velde
Journal:  Ann Oncol       Date:  2014-12-05       Impact factor: 32.976

8.  Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

Authors:  Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

9.  Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.

Authors:  R Glynne-Jones; N Counsell; P Quirke; N Mortensen; A Maraveyas; H M Meadows; J Ledermann; D Sebag-Montefiore
Journal:  Ann Oncol       Date:  2014-04-08       Impact factor: 32.976

Review 10.  A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.

Authors:  Yi Li; Ji Wang; Xiaowei Ma; Li Tan; Yanli Yan; Chaofan Xue; Beina Hui; Rui Liu; Hailin Ma; Juan Ren
Journal:  Int J Biol Sci       Date:  2016-07-17       Impact factor: 6.580

View more
  5 in total

1.  Zinc finger of the cerebellum 5 promotes colorectal cancer cell proliferation and cell cycle progression through enhanced CDK1/CDC25c signaling.

Authors:  Abuduzhayier Maimaiti; Abulaiti Aizezi; Jianati Anniwaer; Buhajar Ali; Mukadas Dilixiati
Journal:  Arch Med Sci       Date:  2019-11-11       Impact factor: 3.318

Review 2.  Recent advances in nanosized metal organic frameworks for drug delivery and tumor therapy.

Authors:  Junlei Yang; Hui Wang; Jinyao Liu; Mengkui Ding; Xianjin Xie; Xiaoyu Yang; Yaru Peng; Shuang Zhou; Ruizhuo Ouyang; Yuqing Miao
Journal:  RSC Adv       Date:  2021-01-14       Impact factor: 3.361

3.  Nomogram to predict cause-specific mortality of patients with rectal adenocarcinoma undergoing surgery: a competing risk analysis.

Authors:  Xu Zhang; Fengshuo Xu; Yadi Bin; Tianjie Liu; Zhichao Li; Dan Guo; Yarui Li; Qiao Huang; Jun Lyu; Shuixiang He
Journal:  BMC Gastroenterol       Date:  2022-02-10       Impact factor: 3.067

Review 4.  Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.

Authors:  Malek Kreidieh; Deborah Mukherji; Sally Temraz; Ali Shamseddine
Journal:  Biomed Res Int       Date:  2020-01-25       Impact factor: 3.411

5.  Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.

Authors:  Ali Shamseddine; Youssef H Zeidan; Malek Kreidieh; Ibrahim Khalifeh; Rim Turfa; Joseph Kattan; Deborah Mukherji; Sally Temraz; Kholoud Alqasem; Rula Amarin; Tala Al Awabdeh; Samer Deeba; Faek Jamali; Issa Mohamad; Mousa Elkhaldi; Faiez Daoud; Mahmoud Al Masri; Ali Dabous; Ahmad Hushki; Omar Jaber; Clement Khoury; Ziad El Husseini; Maya Charafeddine; Monita Al Darazi; Fady Geara
Journal:  BMC Cancer       Date:  2020-09-01       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.